Please enable JS

Blue Companion

BLUE COMPANION provides digital services for health through private-public partnership projects. They also offer CRO services by designing and conducting clinical studies, as well as providing project management and study management services. Their privileged therapeutic domains are neurodegenerative and neuromuscular diseases, as well as ophthalmology.

 

BLUECompanion also designs, deploys and manages customised integrated ICT platforms to treat and monitor on quasi real time different data sources (auto-evaluation questionnaires, wearable devices, robotic interfaces, mobile phones…).

 

Learn more: www.bluecompanion.eu

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

Telemedicine Technologies will be at Swiss Biotech Day 2025

April 29, 2025

May 5 & 6 – Basel Telemedicine Technologies is pleased to present its CleanWeb™ eClinical suite, offering flexible, regulatory-compliant solutions tailored to every phase of clinical trials. Our platform includes a wide range of modules, such as eCRF, Randomization & Trial Supply Management, ePRO, eTMF, eConsent, Data Visualization, Vigilance, Imaging, CTMS, and more. We invite […]

READ MORE
telemedecine technologies news

Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return

April 29, 2025

Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]

READ MORE
telemedecine technologies news

Adopting Flexible Strategies to Combat Capacity Shortages

April 29, 2025

Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]

READ MORE